<< Unique life science-focused application for social media site launched | PerkinElmer and Gilson announce MS collaboration to support pharmaceutical and biotech scientists >>

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Dansk | Nederlands | Finnish | Русский | Svenska

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

Published on November 19, 2009 at 3:13 AM · No Comments

Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan^® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL).

The FDA has not requested any new data to complete its review of these applications. Genentech and Biogen Idec will continue final label discussions with the FDA and are committed to making Rituxan in combination with FC an FDA-approved option for people with CLL.

http://www.biogenidec.com

7169822c-90e7-4db1-bb27-26e0162bbe54|0|.0

Posted in: Medical Condition News | Pharmaceutical News

Tags: Anthracycline, Antibody, Arthritis, Biotechnology, Bone, Bone Marrow, Brain, Cancer, Cell, Chemotherapy, Chronic Lymphocytic Leukemia, Cough, Cyclophosphamide, Headache, Hepatitis B, Leukemia, Lymphoma, Methotrexate, Multiple Sclerosis, Nausea, Rheumatoid Arthritis, Rituximab, Virus

Related posts

FDA sets Feb. 9 for ODAC meeting to review CTI's resubmitted pixantrone NDACell Therapeutics, Inc. (CTI) announced today that on February 9, 2012 the U.S. Food and Drug Admini...
Memgen to present ISF35 clinical trial data on CLL at 53rd ASH meetingMemgen, LLC announces the following abstract on ISF35, the Company's lead product, will be presented...
ChemoCentryx commences CCX168 Phase II trial in ANCA-associated vasculitisChemoCentryx, Inc., today announced the initiation of a Phase II clinical trial for CCX168, an orall...
Six new Bristol-Myers Squibb grants to reduce cancer disparities in CEEThe Bristol-Myers Squibb Foundation today announced six new grants totaling more than $900,000 that ...
New review finds inconsistency in studies that examine link between CCSVI and MSStudies that examined the possible link between vein blockages and multiple sclerosis are so inconsi...
Echo net loss for first half 2011 increases to $6.5 millionEcho Therapeutics, Inc., a company developing its needle-free Symphony tCGM System as a non-invasive...
New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE)...
Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patientsCentocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Appli...
Researchers identify new regulator that play a critical role in B cell developmentA team at the Institut de recherches cliniques de Montr-al led by Dr. Tarik M-r-y, President and Sci...
UCB presents P3, P4 clinical trial data for Crohn's disease at ACG Scientific MeetingFindings from the PRECiSE 3 (P3) open label extension study for Cimzia, demonstrating the longest co...
Study reveals no evidence of link between bisphosphonates to esophageal cancer riskAlthough some reports have suggested a link between the use of oral bisphosphonates (drugs that prev...
Zogenix secures $35M financing for commercial launch of SUMAVEL DosePro needle-free delivery systemZogenix, Inc., a privately held pharmaceutical company, announced that it has secured a $35 million ...
AdnaGen signs option agreement to license specific antibodies to KellBenxAdnaGen AG, a subsidiary of OncoVista Innovative Therapies, Inc., a high-growth global biotech compa...
BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trialsBrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeut...
New study on the factors that determine development of posttraumatic stress disorderAfter exposure to extreme life stresses, what distinguishes the individuals who do and do not develo...
Corticosteroid and antiviral agent combination proves to be beneficial for treating Bell PalsyAmong patients with Bell Palsy, a facial paralysis with unknown cause, treatment with corticosteroid...
Chronic inflammation triggers cell fusions that could protect neuronsChronic inflammation triggers bone marrow-derived blood cells to travel to the brain and fuse with a...
Children with Asperger syndrome have a high prevalence of some sleep disordersThe first known attempt to evaluate the sleep patterns of children with Asperper Syndrome (AS), taki...
Study on Anagen effluvium - common side effect of chemotherapyA new study published in the journal Dermatology shows that hair loss through anagen effluvium induc...
Drug trial goes wrong and six end up intensive careAfter taking part in a clinical trial of a new drug six men are now seriously ill in a north London ...
Discovery of mechanism in the body that could lead to autoimmune diseasesResearchers at National Jewish Medical and Research Center have discovered a mechanism in the body t...
Children who survive cancer face educational difficulties and social isolationA new study finds children who survive cancer have about twice the rate of educational and social pr...
Single dose phase I data on CG53135 for the prevention of oral mucositisCuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for t...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.